Is risperidone contraindicated with tirzepatide (Mounjaro)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 27, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

From the Research

There is no known contraindication between risperidone and tirzepatide, and these medications can generally be used together when clinically appropriate. Risperidone is an antipsychotic medication used to treat conditions like schizophrenia and bipolar disorder, while tirzepatide (Mounjaro, Zepbound) is a GLP-1/GIP receptor agonist used for type 2 diabetes and weight management. These medications work through different mechanisms and target different body systems - risperidone primarily affects neurotransmitters in the brain, while tirzepatide influences insulin secretion, glucose metabolism, and appetite regulation.

Key Considerations

  • Patients should be aware that both medications can potentially cause gastrointestinal side effects, so monitoring for symptoms like nausea or constipation is advisable when using them together 1, 2.
  • Additionally, risperidone can sometimes cause weight gain and metabolic changes, which might be counteracted by tirzepatide's weight-reducing effects 3, 4.
  • As with any medication combination, patients should inform all their healthcare providers about all medications they are taking and report any unusual side effects promptly.

Safety Profile of Tirzepatide

  • The safety profile of tirzepatide is generally acceptable, similar to GLP-1 RAs, with a low risk of hypoglycemia 2, 5.
  • However, patients should be aware of the potential for gastrointestinal side effects, such as nausea and diarrhea, which are dose-dependent 1, 2.
  • The rates of fatal adverse events, severe hypoglycemia, acute pancreatitis, cholelithiasis, and cholecystitis are extremely low (≤ 1%) across all doses of tirzepatide 1.

Clinical Use

  • Tirzepatide has been shown to achieve better glycemic control and weight loss compared to other diabetic medications 3, 4.
  • The SURPASS clinical trial program has demonstrated significant improvements in glycosylated hemoglobin and weight loss in patients with type 2 diabetes 3, 4.
  • As with any medication, the benefits and risks of using tirzepatide should be carefully considered, and patients should be monitored regularly for any adverse effects 5.

References

Research

Adverse Events Related to Tirzepatide.

Journal of the Endocrine Society, 2023

Research

Tirzepatide for type 2 diabetes.

Drugs in context, 2023

Research

Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects.

Diabetes therapy : research, treatment and education of diabetes and related disorders, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.